At the core of this innovation lies a triple-functional vitamin-integrated nanoplatform designed to synergize three crucial capabilities: enhanced immunotherapy, precision-targeted drug delivery, and integrated diagnostic monitoring. Unlike traditional nanocarriers often hindered by issues like the polyethylene glycol (PEG) dilemma or off-target toxicity, vitamin-derived nanoparticles leverage intrinsic biocompatibility, metabolic activity, and receptor-specific targeting to navigate and modulate the recalcitrant tumor microenvironment. This integration promises to reshape therapeutic outcomes by simultaneously stimulating immune responses, ensuring precise drug delivery to malignant sites, and enabling real-time, non-invasive monitoring of treatment efficacy.

Immunomodulation emerges as a cornerstone of this strategy. Fat-soluble vitamins such as vitamins A, D, E, and K assume pivotal roles in reprogramming immune cell function within the tumor milieu. Vitamin A, through retinoic acid-loaded polymeric nanoparticles, has demonstrated the ability to inhibit pro-tumorigenic M2 macrophage polarization and promote dendritic cell maturation. These immunostimulatory effects facilitate a rebalancing of T-helper cell subsets, fostering an antitumor Th1 response. Importantly, preclinical data reveal that such nanocarriers, when combined with immune checkpoint blockade (anti-PD-L1), produce a compounded reduction in tumor progression and inhibit epithelial-to-mesenchymal transition, a process key to metastasis.

Vitamin D-based nanoplatforms introduce a compelling biomimetic approach, exploiting vitamin D3-functionalization to coat manganese dioxide nanoparticles with neutrophil membranes. This design uniquely engages the cGAS-STING pathway, a pivotal DNA-sensing mechanism that reinvigorates suppressed innate immunity within the tumor environment while crossing the notoriously restrictive blood-brain barrier. The result is a marked extension in survival among glioblastoma models, significantly outstripping improvements offered by conventional chemotherapeutics, underscoring the promise of vitamin D derivatives in treating aggressive brain cancers.

Vitamin E-centered nanocarriers further exemplify the immunotherapeutic potential of vitamins. α-Tocopheryl succinate-loaded liposomes exert strong anti-inflammatory effects by downregulating the NF-κB and STAT3 pathways, key drivers of tumor immune evasion. Such modulation reduces the expression of PD-L1, a critical immune checkpoint molecule, thereby enhancing antigen presentation and cytotoxic T-cell responses. Advanced vitamin E scaffolds designed for mRNA delivery achieve near-complete inhibition of tumor growth in prophylactic cancer models, demonstrating the scalability of vitamin-based delivery platforms in nucleic acid therapies.

The incorporation of vitamin K into metal-organic framework nanoplatforms reveals another dimension of immune activation. For example, VK3@Co–Fc complexes initiate immunogenic cell death via redox cycling mechanisms, significantly increasing infiltration of cytotoxic CD8⁺ T cells and markedly reducing metastatic burden in breast cancer models. These findings illuminate vitamin K’s underexplored role as a powerful immunomodulatory agent capable of transforming the immunological landscape within tumors.

Water-soluble vitamins are equally instrumental in this evolving therapeutic schema. Folate-targeted nanogels encapsulating siRNA harness the differential expression of the folate receptor alpha (FRα) in cancer cells to achieve enhanced gene silencing of vascular endothelial growth factor (VEGF), a driver of tumor angiogenesis, thus remodeling the tumor microenvironment. Similarly, vitamin B3 (niacin) engages GPR109A receptors to suppress immunosuppressive myeloid populations and augment cytotoxic T-lymphocyte activity, revealing the immunometabolic intersections that vitamin derivatives can exploit.

Vitamin C’s capacity to target cancer stem cells is realized through its conjugation to gold nanoparticles, enhancing selective cytotoxicity. Moreover, combinatorial liposomal formulations of vitamin C with indocyanine green induce polarization shift from tumor-supportive M2 macrophages to pro-inflammatory M1 phenotypes, a critical pivot in reversing immune suppression. In bladder cancer models, this approach demonstrates an impressive ~90% tumor growth inhibition when integrated with anti-PD-L1 therapy, showcasing potent synergism between vitamin-derived immunomodulation and checkpoint blockade.

Beyond immunotherapy, vitamin-integrated nanoplatforms tackle the formidable pharmacological barriers that have historically limited anticancer agents’ efficacy. Nanoencapsulation techniques leverage lipidic and polymeric carriers to improve vitamin bioavailability, control release kinetics, and minimize off-target toxicities. For instance, liposomal all-trans retinoic acid circumvents rapid hepatic metabolism, enhancing systemic exposure and tolerability in clinical settings. Concurrently, vitamins function as structural elements and targeting moieties. Folate and vitamin B12 derivatives enable receptor-mediated endocytosis, improving cellular uptake with high specificity, while vitamin E-derived TPGS acts as both a surfactant and multidrug resistance modulator, drastically elevating intracellular concentrations of agents like paclitaxel in resistant cancer phenotypes.

The therapeutic impact is amplified by co-delivery strategies. Vitamin B2-based ferric chloride nanocomplexes serve as sonosensitizers, generating reactive oxygen species (ROS) upon ultrasound activation. When combined with metformin, these platforms achieve substantial tumor suppression in triple-negative breast cancer, a particularly aggressive and treatment-resistant subtype. Such multifunctional designs underscore the versatility and adaptability of vitamin-integrated nanomedicine.

An essential frontier lies in the seamless incorporation of diagnostics with therapy—the theranostic paradigm. Vitamin-targeted near-infrared probes enable ultra-sensitive detection of FRα-positive tumors, achieving remarkably high tumor-to-normal tissue contrast ratios critical for early intervention. Iodinated nanoemulsions with vitamin E cores facilitate persistent high-contrast micro-CT imaging, sustaining visualization over months. Multifunctional constructs like TPGS-coated upconversion nanoparticles co-delivering chemotherapeutics and imaging agents provide real-time, fluorescence resonance energy transfer-based monitoring of drug release, enabling precise dosing adjustments and improved treatment responsiveness, particularly in multidrug resistant cancers.

However, translating these exciting preclinical advances into clinical practice remains fraught with challenges. Key concerns revolve around long-term biocompatibility and potential organ accumulation, such as hepatic sequestration of inorganic nanoparticles, that could precipitate unforeseen toxicities or immune dysregulation. The complexity of scalable manufacturing methods, including microfluidics-based encapsulation, demands rigorous standardization to ensure batch consistency and regulatory compliance. Additionally, heterogeneous vitamin receptor expression across diverse tumor types underscores the necessity for robust patient stratification protocols or multiplexed targeting strategies to optimize efficacy and minimize off-target effects.

Looking forward, the integration of artificial intelligence (AI) and multi-omics technologies is poised to accelerate the rational design of vitamin-based nanocarriers and enable personalized treatment regimens. The convergence of nutrient biology with nano-immunoengineering heralds a new era in oncology, where patients receive precision-tailored interventions that harness the full immunobiological potential of vitamins. Emerging modalities such as chimeric antigen receptor T-cells (CAR-T) and oncolytic viruses could synergize with these platforms, enhancing therapeutic depth and durability.

This comprehensive review underscores that by reimagining vitamins not merely as dietary supplements but as molecular architects of nanotherapeutics, researchers can unlock unprecedented avenues to surmount the complexity of cancer. The paradigm of vitamin-engineered nanoplatforms signals a paradigm shift toward holistic, “see-and-treat” oncology solutions that integrate cutting-edge immunotherapy, optimized drug delivery, and robust diagnostic capabilities. As Dr. Zichao Luo emphasizes, bridging nutrient science with precision medicine through these innovative nanotechnologies presents a transformative frontier—one whose clinical realization could significantly improve outcomes and quality of life for cancer patients worldwide.

Subject of Research: Vitamin-Engineered Nanoplatforms for Precision Oncology Integrating Immunotherapy, Drug Delivery Systems, and Theranostics

Article Title: Vitamin‐Engineered Nanoplatforms in Precision Oncology: Integrating Immunotherapy, Delivery Systems, and Theranostics

News Publication Date: 15-Oct-2025

Web References: http://dx.doi.org/10.1002/mba2.70028

Image Credits: Hailong Zhang and Zichao Luo

Keywords: precision oncology, vitamin-derived nanoplatforms, immunotherapy, drug delivery, theranostics, tumor microenvironment, nanoparticle targeting, vitamin A, vitamin D, vitamin E, vitamin K, vitamin B complex, vitamin C, nano-immunoengineering

The LiBIO score utilizes a blood-based liquid biopsy technique, a non-invasive approach gaining momentum for its ability to provide dynamic insights into the molecular and immune landscape of cancer patients. The model specifically predicts patient responsiveness to immune checkpoint blockade (ICB) drugs, a class of immunotherapies that have shown remarkable success by unleashing the immune system’s ability to target and destroy tumor cells. By assessing circulating immune cells through serial liquid biopsies, the LiBIO approach offers a real-time window into the evolving cancer-immunity interplay, allowing clinicians to intervene promptly and tailor treatments for optimal outcomes.

Dr. Kun Wang, assistant professor of comparative biosciences and bioengineering, highlights the significance of this advancement. Head and neck squamous cell carcinoma (HNSCC), the focus of this study, often exhibits variable responses to immunotherapy, complicating treatment strategies. “Current clinical practice lacks reliable, minimally invasive biomarkers capable of predicting which patients will derive benefit from ICB therapies,” Wang explains. The LiBIO score fills this critical gap by enabling precise early identification of responders, sparing non-responders from unnecessary treatment-related toxicity and enabling more efficient resource allocation.

Underlying the LiBIO score is a detailed analysis of immune cell populations within peripheral blood samples taken before and after ICB administration. Leveraging a mouse model of HNSCC, the researchers conducted longitudinal monitoring to capture immune dynamics over time. Intriguingly, they identified that an early post-treatment increase in specific subsets of ‘cancer-fighting’ immune cells—namely, effector memory T cells and B cells—correlated strongly with positive therapeutic outcomes. Effector memory T cells are known for their rapid response to tumor antigens, while B cells contribute through antibody production and antigen presentation, suggesting a synergistic immune response to the tumor microenvironment induced by ICB therapy.

The temporal aspect of monitoring was critical in demarcating effective immune activation. Recognizing and validating an optimal early time point post-therapy initiation allowed the scientists to pinpoint a gene expression signature tied to the relevant immune cellular subsets. This gene signature forms the molecular basis of the LiBIO score, serving as a surrogate biomarker that captures the immune system’s readiness to mount an effective anti-tumor attack. This approach contrasts with previous static or invasive tumor biopsies, which fail to dynamically reflect evolving immune responses during treatment.

The predictive accuracy of the LiBIO model surpasses that of existing biomarkers, which often rely on tumor mutational burden or PD-L1 expression levels and yield inconsistent predictive power. Impressively, the LiBIO score demonstrates broad applicability beyond HNSCC, showing promise in predicting immunotherapy responses in malignancies such as breast cancer, lung cancer, and melanoma. This generalizability underscores the pivotal role of systemic immune parameters over tumor-intrinsic factors alone, expanding the clinical utility across diverse cancer types.

The clinical implications of adopting the LiBIO score are profound. By stratifying patients according to their likelihood of benefiting from ICB therapies, clinicians can personalize treatment regimens, reducing exposure to ineffective therapies and associated adverse effects. Moreover, the blood-based nature of this test allows for frequent, minimally invasive monitoring of patients’ immune status during therapy, facilitating dynamic treatment adjustments. Dr. Wang emphasizes, “This tool not only improves therapeutic precision but also empowers clinicians with molecular-level insights during the critical phases of immunotherapy.”

Buoyed by these promising preclinical results, the research team is actively seeking to translate the LiBIO score into clinical trials involving human patients. Dr. Robert Saddawi-Konefka, a key collaborator and physician-scientist at MD Anderson Cancer Center, is spearheading efforts to design and propose trials aimed at validating the biomarker’s predictive power in diverse clinical settings. Although timelines for initiation remain tentative, the groundwork laid by this multi-institutional collaboration instills confidence that human application is imminent.

Future studies will delve deeper into the mechanistic underpinnings of the immune interactions captured by the LiBIO score. While it is established that both effector memory T cells and B cells contribute to enhanced immunotherapy responses, the molecular and cellular crosstalk that potentiates this synergy remains elusive. The research team aims to unravel the precise pathways through which B cells augment T cell-mediated anti-tumor activity. Insights gained may enable the design of next-generation combination immunotherapies that deliberately enhance this interaction to amplify treatment efficacy and overcome resistance.

This pioneering work also raises intriguing questions about the dynamic immune landscape during cancer treatment. The deployment of liquid biopsies to assess immune repertoire diversity—through T cell receptor (TCR) and B cell receptor (BCR) analyses—provides a window into adaptive immune evolution under therapeutic pressure. Understanding how these repertoires shift in responders versus non-responders may identify novel therapeutic targets or resistance mechanisms, heralding a paradigm shift in immunotherapy monitoring.

As the field of cancer immunotherapy advances, tools like the LiBIO score exemplify the fusion of cutting-edge molecular profiling with clinical oncology. By integrating immune biomarkers into treatment algorithms, oncology is moving towards highly personalized interventions that optimize patient outcomes while minimizing unnecessary toxicity. This approach aligns with the broader vision of precision medicine, where dynamic patient-specific data guides not only therapy selection but also real-time adjustments.

In summary, the development of the LiBIO score represents a critical stride in overcoming one of immunotherapy’s major hurdles—the variability in patient response. By exploiting a combination of blood-based immune profiling and longitudinal tracking, this biomarker facilitates early and accurate prediction of treatment success. Its impending clinical translation could revolutionize immunotherapy protocols across multiple cancer types, making treatments safer, more effective, and more accessible. This advancement embodies the promise of translational research to deliver tangible benefits to patients battling cancer worldwide.

Subject of Research:
Immune biomarker development and predictive modeling for immunotherapy response in head and neck squamous cell carcinoma through longitudinal liquid biopsies.

Article Title:
Longitudinal liquid biopsy identifies an early predictive biomarker of immune checkpoint blockade response in head and neck squamous cell carcinoma

News Publication Date:
1-Sep-2025

Web References:
https://www.nature.com/articles/s41467-025-63538-4

References:
Wang, K. et al. Longitudinal liquid biopsy identifies an early predictive biomarker of immune checkpoint blockade response in head and neck squamous cell carcinoma. Nature Communications (2025). DOI: 10.1038/s41467-025-63538-4

Keywords:
Head and neck cancer, immune checkpoint blockade, immunotherapy, liquid biopsy, effector memory T cells, B cells, predictive biomarker, cancer immunotherapy, immune monitoring, precision oncology

The PLAGAST prospective biomarker study marks a significant milestone in oncological precision medicine by systematically evaluating ctDNA as a longitudinal biomarker during neoadjuvant chemotherapy and surgical intervention. Historically, tissue biopsies provided a static snapshot of the tumor genotype, but these samples often fail to capture the complex and evolving heterogeneity within a tumor mass or between primary and metastatic sites. By contrast, ctDNA offers a real-time molecular portrait, capable of reflecting tumor burden, clonal evolution, and the emergence of resistant subpopulations with remarkable sensitivity.

Gastric adenocarcinoma and gastroesophageal junction tumors represent a major global health burden with high mortality rates. Traditional treatment strategies often involve perioperative chemotherapy combined with surgical resection, yet recurrence remains frequent, underscoring the need for biomarkers that can guide therapeutic decisions. The study’s longitudinal design allowed researchers to collect serial plasma samples at defined treatment milestones: baseline pre-treatment, during chemotherapy cycles, and post-resection. This enabled them to map ctDNA dynamics to clinical outcomes, providing crucial insights into treatment efficacy and micrometastatic disease.

One of the transformative aspects of this research is the demonstration that ctDNA levels correlate strongly with radiological tumor responses, potentially outpacing conventional imaging modalities in sensitivity and temporal resolution. The team observed that patients who achieved complete pathological response exhibited rapid clearance of ctDNA, whereas persistent or rising ctDNA levels during therapy were harbingers of poor prognosis. This finding suggests that early ctDNA kinetics could serve as an actionable biomarker, guiding oncologists to tailor treatment intensity or explore alternative therapeutic regimens before clinical progression becomes apparent.

Beyond monitoring response, the study delved deeply into the mutational landscape uncovered through ctDNA sequencing. By employing high-depth next-generation sequencing panels, the researchers identified recurrent mutations and structural alterations characteristic of gastric and gastroesophageal adenocarcinomas. The ability to capture this genomic information non-invasively unlocks avenues for personalized targeted therapies, such as tyrosine kinase inhibitors or immune checkpoint blockade, tailored to the molecular profile of each patient’s tumor as revealed by their ctDNA.

Importantly, the PLAGAST study also highlights the temporal heterogeneity of tumor clones under therapeutic pressure. The gradual disappearance of some variants juxtaposed with the emergence of new, treatment-resistant clones speaks to the Darwinian evolutionary battle within the patient. This evolutionary insight not only underscores the dynamic nature of these cancers but also provides a rational framework for combination therapies designed to preempt resistance mechanisms, potentially improving long-term survival.

The researchers faced significant technical challenges inherent to ctDNA analysis, notably the low abundance of tumor-derived fragments amidst a vast background of normal circulating DNA. To overcome this, they optimized sensitive library preparation protocols and bioinformatics pipelines capable of distinguishing true somatic mutations from sequencing artifacts. Their success establishes a methodological precedent that can be adapted to other malignancies, broadening the clinical applicability of ctDNA.

Moreover, the prospective design of the PLAGAST trial allowed the team to prospectively evaluate the predictive power of ctDNA, distinguishing it from retrospective biomarker discovery studies that lack temporal and clinical contextualization. This rigorous approach strengthens the clinical validity of their findings and paves the way for integrating ctDNA monitoring into routine management algorithms for patients with gastric cancer and potentially other solid tumors.

Such integration into clinical practice could alter the therapeutic landscape profoundly. For instance, dynamic ctDNA readouts could inform decisions about the timing of surgery, the need for adjuvant therapies, or closer surveillance schedules. If ctDNA clearance is confirmed as an early indicator of complete remission, patients might be spared the morbidities associated with overtreatment, whereas those with persistent ctDNA positivity could receive intensified or alternative regimens.

The implications extend beyond individual patient care to the design of future clinical trials. Using ctDNA as an endpoint could accelerate the evaluation of novel agents by providing early molecular evidence of efficacy, reducing reliance on long-term survival outcomes which delay drug approvals. Additionally, adaptive trial designs could incorporate ctDNA dynamics to stratify patients more effectively, enhancing the overall trial efficiency and precision.

Critically, the study also sets the stage to explore the potential of ctDNA in minimal residual disease (MRD) detection after curative-intent surgery. The ability to detect subclinical residual cancer cells through ctDNA could trigger early interventions, potentially preventing relapse and improving survival rates. Furthermore, detection of MRD might guide enrollment into adjuvant trials or inform decisions about immunotherapy, a rapidly advancing domain in gastroesophageal oncology.

The comprehensive nature of the PLAGAST study’s findings represents a leap forward in understanding the molecular underpinnings and clinical utility of ctDNA in gastric and gastroesophageal adenocarcinomas. The prospective, longitudinal design coupled with rigorous molecular analyses lays a robust foundation for biomarker-driven personalized oncology approaches. As the field advances, integration of ctDNA monitoring could become a standard of care, heralding a new era in managing these challenging cancers where time-sensitive molecular insights can save lives.

In conclusion, the research by Zaanan and colleagues ushers in a paradigm shift in the oncological monitoring of gastric and gastroesophageal junction adenocarcinomas. Through meticulous longitudinal ctDNA tracking, the study demonstrates that this molecular tool provides powerful prognostic and predictive information, surpassing traditional imaging and static tissue biopsies. As clinical validation continues and technology improves, ctDNA has the potential to transform patient care by enabling truly personalized and dynamic cancer therapy in one of oncology’s most intractable disease settings.

The promise of this research extends widely. Beyond gastric cancers, the PLAGAST study’s framework offers a blueprint for incorporating ctDNA into clinical workflows across cancer types. The fusion of molecular biology, longitudinal sampling, and advanced data analytics represents a convergence that will define future cancer care. Ultimately, this study highlights the extraordinary possibilities unleashed when technology meets clinical insight, offering renewed hope to patients and clinicians battling formidable malignancies.

Subject of Research: Longitudinal circulating tumor DNA analysis in treatment monitoring of locally advanced resectable gastric and gastroesophageal junction adenocarcinoma.

Article Title: Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker study.

Article References:
Zaanan, A., Didelot, A., Broudin, C. et al. Longitudinal circulating tumor DNA analysis during treatment of locally advanced resectable gastric or gastroesophageal junction adenocarcinoma: the PLAGAST prospective biomarker study. Nat Commun 16, 6815 (2025). https://doi.org/10.1038/s41467-025-62056-7